Press coverage about Derma Sciences (NASDAQ:DSCI) has trended positive on Tuesday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Derma Sciences earned a daily sentiment score of 0.31 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 44.8753531327099 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Derma Sciences (NASDAQ:DSCI) opened at $7.00 on Tuesday. Derma Sciences has a 12 month low of $2.92 and a 12 month high of $7.05.

ILLEGAL ACTIVITY WARNING: “Derma Sciences (DSCI) Receives Media Impact Score of 0.31” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/derma-sciences-dsci-receives-media-impact-score-of-0-31/1717498.html.

Derma Sciences Company Profile

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insider Buying and Selling by Quarter for Derma Sciences (NASDAQ:DSCI)

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.